Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
DETECT
1 other identifier
observational
5
1 country
1
Brief Summary
The physiopathology of trigeminal-autonomic cephalalgia, and more particularly of cluster headache (CH) is still partially unknown. Three main structures are involved: the trigeminovascular system, the cephalic afferents of the autonomic nervous system, and centrally the hypothalamus. There are many clinical arguments in favor of the involvement of the hypothalamus in CH. In addition, several radiological studies have confirmed the involvement of the posterior hypothalamic region in cluster attacks. Thus, a positron emission tomography study showed hyperactivity of the posteroinferior nucleus of the ipsilateral hypothalamus. Voxel based MRI studies have shown a bilateral increase in the volume of the inferoposterior part of the homolateral hypothalamus. The involvement of the posterior hypothalamic region or more precisely the ventral tegmental area of the midbrain therefore seems acquired, although its real role as a generator or modulator of pain remains to be precised. Deep brain stimulation (dBS) is used in the management of chronic drug-resistant CH with an overall efficacy in 2/3 of patients. Nevertheless, its mechanism of action remains poorly understood, thus limiting the selection of patients and the optimization of care. The lack of clear neurophysiological criteria to identify the neuronal population to be targeted is a major source of uncertainty in the positioning of dBS electrodes and parameters adjustment. In order to improve the understanding and at the same time the results of this technique, obtaining in vivo electrophysiological data seems mandatory. Local fields potentials (LFP) have been recordered by in vivo by dBS in other diseases (Parkinson's disease, tremor…) and their analysis has brought new insigights in the characterization and understanding of these pathology. New generations of neurostimulator (Percept Medtronic) enables continuous recording of LFP in implanted patients. The goal of our study is the recording of LFP at the time of CH attacks via the BrainSenseTM system. This system included in the stimulator allows in vivo collection of LFP in the absence and presence of stimulation. The pathophysiological data recordered will then be correlated with the clinical benefit of the dBS ( nulber of attacks, duration, pain intensity…). As it is a feasibility study, only 5 patients will be included.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 5, 2023
CompletedFirst Posted
Study publicly available on registry
May 12, 2023
CompletedStudy Start
First participant enrolled
May 31, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedMay 12, 2023
April 1, 2023
2 years
April 5, 2023
May 10, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Local field potentials
Local field potentials amplitudes registered by the patient during a cluster attack
Between 0 to 12 months
Secondary Outcomes (4)
Change in Efficacy of deep brain stimulation on attacks frequency
Between 0 to 12 months
Change in Efficacy of deep brain stimulation on pain intensity
Between 0 to 12 months
Change Efficacy of deep brain stimulation in attacks duration
Between 0 to 12 months
Change in Efficacy of deep brain stimulation on treatment
Between 0 to 12 months
Interventions
Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation
Eligibility Criteria
Patients suffering from refractry chronic cluster headache
You may qualify if:
- Adult patients (age : 18-70 years-old) suffering from refractory chronic cluster headache
- Patients eligible for a deep brain stimulation in the ventral tegmental area of the mesencephalon
- Patients implanted with a deep brain stimulation system PerceptTM Medtronic®
You may not qualify if:
- Secondary cluster headache
- Patients implanted with another device of deep brain stimulation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assistance Publique Hopitaux de Marseille
Marseille, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 5, 2023
First Posted
May 12, 2023
Study Start
May 31, 2023
Primary Completion
June 1, 2025
Study Completion
June 1, 2025
Last Updated
May 12, 2023
Record last verified: 2023-04